Regulatory Landscape of Trastuzumab Biosimilars: Updates and Implications for 2024
Trastuzumab - Biosimilars Insight, 2024
Trastuzumab, a monoclonal antibody targeting HER2-positive breast cancer, has revolutionized the treatment landscape since its approval. As patents for the originator product have begun to expire, biosimilar versions of Trastuzumab have emerged, aiming to provide...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Romaian
Portuguese (Brazil)
Greek